Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Torque Therapeutics
Finance Watch: Biotech Venture Capital Had Its Biggest Quarter Ever
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
Repertoire Launches To Turn Immune System Insights Into T-Cell Therapies, Vaccines
Flagship Pioneering combined Torque Therapeutics and Cogen Immune Medicines, which have raised more than $220m, into Repertoire Immune Medicines with an autologous T-cell therapy being studied in a Phase I trial.
Venture Funding Deals: Semma, Arcus Raise $100m-Plus For Cancer, Diabetes Therapies
Semma's $114m Series B round and a $107m Series C for Arcus top November's list of biopharmaceutical venture capital deals. Forty Seven, Medeor and Tricida also closed sizeable rounds.
Finance Watch: Semma Raises $114m As VC Funding Keeps Up Brisk Pace
Semma closed a $114m Series B round to fund development of insulin-producing cells. Also, Tesaro and Catalyst are among recent public company financings, while Otonomy shifted gears, laying off sales staff.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Cogen Immune Medicines
- Cogen Therapeutics
- Repertoire Immune Medicines
- Torque Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.